ReviewExpert review of anti-infective therapy2017
Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings.
Review in Expert review of anti-infective therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Headache as a Predictor of Cryptococcal Meningitis in Ambulatory Patients With Symptomatic HIV-associated Cryptococcal Antigenemia.Open forum infectious diseases · 2026Article
- Establishment of a novel scoring model for mortality risk prediction in HIV-infected patients with cryptococcal meningitis.BMC infectious diseases · 2021Article
- The Repurposing of Acetylsalicylic Acid as a Photosensitiser to Inactivate the Growth of Cryptococcal Cells.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Disseminated coccidioidomycosis in a patient who is immunocompromised in the setting of immune reconstitution inflammatory syndrome.BMJ case reports · 2021Article
- Asymptomatic cryptococcal antigenemia in HIV-infected patients: a review of recent studies.Chinese medical journal · 2020Review
- Surgical treatment and operation time in human immunodeficiency virus-negative cryptococcal meningitis.Medicine · 2020Article
- Molecular Epidemiology Reveals Low Genetic Diversity amongPathogens (Basel, Switzerland) · 2020Article
- The utility of cerebrospinal fluid white cell count during the prognostic assessment for cryptococcal meningitis patients: a retrospective study.BMC infectious diseases · 2020Article
- Derivatives of the Antimalarial Drug Mefloquine Are Broad-Spectrum Antifungal Molecules with Activity against Drug-Resistant Clinical Isolates.Antimicrobial agents and chemotherapy · 2020Article
- New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformansAntimicrobial agents and chemotherapy · 2020Article
- Diagnosis and Management of Central Nervous System Cryptococcal Infections in HIV-Infected Adults.Journal of fungi (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionRecent advances in the treatment and prevention of cryptococcal meningitis have the potential to decrease AIDS-related deaths. Areas covered: Targeted screening for asymptomatic cryptococcal antigenemia in persons with AIDS is a cost effective method for reducing early mortality in patients on antiretroviral therapy. For persons with symptomatic cryptococcal meningitis, optimal initial management with amphotericin and flucytosine improves survival compared to alternative therapies; however, amphotsericin is difficult to administer and flucytosine has not been available in middle or low income countries, where cryptococcal meningitis is most prevalent. Expert commentary: Improved care for cryptococcal meningitis patients in resource-limited settings is possible, and new treatment possibilities are emerging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.